Upon joining the study, you will be randomly assigned to one of two treatment groups. This is done by chance, similar to flipping a coin.

One group will receive empasiprubart, which is the investigational medication being tested. The other group will receive intravenous immunoglobulin (also called IVIg), which is a standard treatment.

Neither you nor your doctor will know which treatment you are receiving during the study. This is called a double-blinded approach and helps ensure accurate results.

You will receive your assigned medication through an intravenous infusion, which means the medication will be delivered directly into your vein through a needle.

The infusions will be administered according to a schedule determined by the study protocol.

Each infusion session will take place at the study site, and the duration of each infusion will be explained to you by the study staff.

Throughout the study, you will undergo regular assessments to measure how your condition is responding to treatment.

Your functional ability will be measured using the aINCAT score, which assesses your ability to perform daily activities involving your arms and legs.

Your overall disability will be evaluated using the I-RODS scale, which measures your ability to perform various tasks.

Your muscle strength will be tested using the MRC Sum Score, which examines the strength of different muscle groups.

Your grip strength will be measured in both hands, with particular focus on your dominant hand.

Your mobility will be assessed using the Timed Up and Go test, which measures how long it takes you to stand up, walk a short distance, turn around, walk back, and sit down.

You will be asked to complete questionnaires about your quality of life, fatigue, pain, and how your condition affects your daily activities and work.

At week 24, a comprehensive evaluation will be conducted to assess the effectiveness of your treatment.

The primary measure will be whether there is a decrease of at least 1 point in your aINCAT score compared to your baseline score at the start of the study.

Additional measurements will include changes in your disability scale scores, muscle strength, grip strength, and mobility compared to baseline.

Throughout the study, your safety will be continuously monitored.

Blood samples will be taken regularly to check for any changes in laboratory values and to measure medication levels in your blood.

The study team will monitor for the development of antibodies, which are proteins your immune system might produce in response to the study medication.

Your heart function will be monitored using electrocardiograms (ECGs), which record the electrical activity of your heart.

Your vital signs, such as blood pressure, heart rate, and temperature, will be measured regularly.

Any side effects or health changes you experience will be recorded and assessed by the study team.

The study will continue beyond week 24, with ongoing treatment and assessments.

You will continue to receive regular infusions and attend scheduled visits for evaluations.

Changes in your condition will be tracked over time to understand the long-term effects of the treatment.

The study is expected to continue until May 2030.

Your individual participation duration will be explained to you by the study team.

Final assessments will be conducted at the end of your participation to evaluate your overall response to treatment and any long-term effects.